Emmaus Life Sciences, Inc.
EMMA · OTCMCIK 822370fmd_097JPDQVYVKVGQ1TH329NH28HMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2009 to Jun 30, 2026, 65 periods
| Line item | FY2017 | FY2018 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 1 | – | 23 | 23 | 21 | 18 | 30 | 17 | 12 |
| Cost of revenue | 0 | – | 1 | 1 | 2 | 3 | 3 | 1 | 1 | 1 |
| Commissions and fees | – | – | – | – | – | – | – | – | – | – |
| Gross profit | 0 | – | 15 | 22 | 21 | 17 | 16 | 28 | 15 | 12 |
| Realized investment gains (losses) | – | – | (44) | (22) | (0) | (0) | – | – | – | – |
| Research and development | – | – | 2 | 2 | 2 | 4 | 2 | 1 | 1 | 0 |
| Selling, general and administrative | 6 | – | 22 | 24 | 19 | 19 | 21 | 24 | 17 | 11 |
| Total operating expenses | 7 | – | 24 | 26 | 21 | 23 | 22 | 25 | 17 | 11 |
| Operating income | (7) | – | (8) | (5) | (0) | (6) | (7) | 4 | (2) | 0 |
| Interest expense | – | – | 23 | 28 | 6 | 3 | 5 | 7 | 5 | 7 |
| Interest and investment income | – | – | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Other non-operating income (expense) | (0) | (0) | – | – | – | – | – | – | – | – |
| Income before taxes | (7) | – | (73) | (55) | 1 | (16) | (11) | (4) | (6) | (7) |
| Income tax expense | 0 | – | 0 | 0 | (0) | 0 | 0 | (0) | 0 | 0 |
| Net income from continuing operations | (7) | – | (73) | (55) | 1 | (16) | (11) | (4) | (6) | (7) |
| Net income | (7) | – | (73) | (55) | 1 | (16) | (11) | (4) | (6) | (7) |
| Net income to common shareholders | (7) | (10) | – | – | – | – | – | – | – | – |